Furoate Nasal Spray

Nasonex nasal spray, 50 meg is a metered-dose, manual-pump spray unit containing an aqueous suspension of mometasone furoate monohydrate equivalent to 0.05% w/w mometasone furoate, calculated on the anhydrous basis, in an aqueous medium containing glycerin, micro- 

Charge item 3 in a suitable dry, stainless steel mixing vessel. 

Add item 2 to step 2 and then add item 1 with constant stirring until clear solution obtained. 

---

LaForce C, Journeay GE, Miller SD, Silvey MJ, Wu W, Lee LA, et al. Ocular safety of fluticasone furoate nasal spray in patients with perennial allergic rhinitis a 2-year study. Arm Allergy Asthma Immunol July 2013 lll(l) 45-50. 

Beclomethasone dipropionate, triamcinolone acetonide, budesonide, flunisolide, and mometasone furoate are available as nasal sprays for the topical treatment of allergic rhinitis. They are effective at doses (one or two sprays one, two, or three times daily) that in most patients result in plasma levels that are too low to influence adrenal function or have any other systemic effects. 

In this chapter, analysis of the excipient in Nasonex (mometasone naral spray) is used as a typical example to demonstrate how to select a proper analytical method. Nasonex Nasal Spray contains Mometasone Furoate, microcrystalline cellulose, and carboxymethylcellulose sodium NF, citric acid USP, sodium citrate USP, benzalkonium chloride solution NF, glycerin USP, polysorbate 80 NF, phenylethyl alcohol USP, and water USP. 

Schering-Plough has developed a once-daily nasal spray formulation of momethasone furoate for the treatment and prevention of seasonal and perennial allergic rhinitis. Inhalation formulations have also been developed. Schering-Plough has developed an inhaled powder formulation for asthma maintenance treatment. 

Mometasone furoate nasal suspension is supplied as an aqueous suspension with an atomizing pump that dispenses 50 pg per metered spray. The total daily dose for mometasone furoate is 200 pg. 

Nasal suspensions can be characterised by thixotropic properties [41]. Nasal sprays containing triamcinolone acetonide or mometasone furoate showed time-dependent, reversible loss of viscosity under shear (shaking or spraying,) flowing more freely. Recovery of viscosity after application is likely to inhibit suspension flowing out from the nasal cavity [42, 43]. 

---